MYM Nutraceuticals Inc., (CSE:MYM) (the “Company” or “MYM”) is pleased to announce the following corporate updates:
MYM Engages Michael Horsfall to Consulting Agreement
MYM shall engage the consultant for a 3-year consulting term commencing on November 23, 2017. Michael Horsfall shall provide MYM with consulting services focused on helping MYM and its partners obtain a license for and construct a medical marijuana production facility in Richmond Valley, Australia. In lieu of consulting fees, MYM shall grant 140,000 options to purchase common shares in the capital of MYM, with an exercise price of $3.37. The options shall vest in accordance with the following schedule, and expire one year after vesting:
(a) 14,000 on the 3-month anniversary of the Effective Date;
(b) 14,000 on the 6-month anniversary of the Effective Date;
(c) 14,000 on the 9-month anniversary of the Effective Date;
(d) 14,000 on the 12-month anniversary of the Effective Date;
(e) 14,000 on the 15-month anniversary of the Effective Date;
(f) 14,000 on the 18-month anniversary of the Effective Date;
(g) 14,000 on the 21-month anniversary of the Effective Date;
(h) 14,000 on the 24-month anniversary of the Effective Date;
(i) 14,000 on the 27-month anniversary of the Effective Date; and
(j) 14,000 on the 30-month anniversary of the Effective Date.
Mr. Horsfall is co-founder and CEO of PUF Ventures Australia Pty and Natures Hemp Australia Pty Ltd.
Mr. Horsfall has worked extensively as a strategic business consultant with various Australian and Internationally listed fortune 100 companies and brings over 20 years’ experience to the role. He has been responsible for successfully leading pursuit and capture teams across Government and Whole-of-Government (WOG) IT Outsourcing Contracts for both Federal and State Governments. Mr. Horsfall has founded numerous companies in the Information Technology, Consulting, Finance, Hospitality and Real Estate sectors. He brings with him an extensive network and relationships combined with an in-depth understanding of business and Government.
MYM Engages Camber Digital to Consulting Agreement
MYM shall engage the consultant for a 1-year consulting term, commencing on January 1, 2018. Camber Digital shall provide MYM with marketing, branding, graphic design, and IT services. MYM shall grant Camber Digital 60,000 options to purchase common shares in the capital of MYM, with an exercise price of $3.37. The options shall vest in accordance with the following schedule, and expire one year after vesting:

  1. (a) 15,000 on the 3-month anniversary of the Start Date;

(b) 15,000 on the 6-month anniversary of the Start Date;
(c) 15,000 on the 9-month anniversary of the Start Date; and
(d) 15,000 on the 12-month anniversary of the Start Date.
MYM Assigns Shares Under Debt Settlement Agreement
MYM assigns to Chrome Holdings (“Chrome”) 175,000 common shares in the capital of MYM to satisfy obligations under the Finder’s Agreement. Chrome, MYM and PUF Ventures Australia are participants in a joint venture to build a medical marijuana facility in Richmond Valley, Australia (“PUF Deal”). MYM owes a finder’s fee equal to 5% of the value of the PUF Deal. Chrome wishes to assume MYM’s obligations under the Finder’s Agreement with respect to the payment of the debt.
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a partner in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca
Investor Relations
Terry Brown
1.855.696.2261
terry@mymarijuana.ca
Join us on our social media channels:
Twitter: @MYM_Nutra
Facebook: @mymcanada
Instagram: @MYM_Nutra
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
Click here to connect with MYM Nutraceuticals Inc. (CSE:MYM) for an Investor Presentation.


Source: www.thenewswire.com

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less